SIGA Receives FDA Approval for Intravenous (IV) Formulation of TPOXX® (tecovirimat) – FDA Approval Provides Important Option for Those Unable to Take TPOXX Oral Formulation –
NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a…